Company Monitoring Page for Merck

latest headlines for company on cafepharma

AstraZeneca, Merck go multilingual for prostate cancer push
Medical Marketing and Media
Mon, 01/23/23 - 09:54 pm
Tags:
AstraZeneca, Merck, pharma marketing, prostate cancer
Merck discovers 'root cause' of nitrosamine levels in blockbuster diabetes drugs
Endpoints
Thu, 01/19/23 - 10:20 am
Tags:
Merck, nitrosamine, diabetes, Januvia, Janumet, drug manufacturing
Biopharma's stock market winners of 2022 revealed
EP Vantage
Wed, 01/18/23 - 09:46 am
Tags:
pharma stocks, Merck, Eli Lilly, AbbVie, Daiichi Sankyo, Vertex Pharmaceuticals, Takeda, Sarepta Therapeutics, Halozyme, Horizon Therapeutics
Chasing Roche, Merck talks up subcutaneous Keytruda ahead of phase 3 data drop
Fierce Pharma
Mon, 01/16/23 - 11:16 am
Tags:
Merck, Keytruda, Roche, cancer, oncology
Big caps bounce back for biopharma
EP Vantage
Mon, 01/16/23 - 11:14 am
Tags:
pharma stocks, Amgen, BeiGene, Bristol Myers Squibb, Gilead Sciences, Lantheus Holdings, Madrigal Pharmaceuticals, Merck, Moderna Therapeutics, Novo Nordisk, Prometheus Biosciences, Roche
Three TIGIT players look to surprise in 2023
EP Vantage
Fri, 01/13/23 - 10:06 am
Tags:
anti-TIGIT, Roche, Merck, Gilead Sciences, Arcus Biosciences
Biopharma’s bolt-on bonanza is set to continue
EP Vantage
Thu, 01/12/23 - 10:18 am
Tags:
M&A, Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Ipsen, Merck, Pfizer
Merck Highlights Growth Strategy at J.P. Morgan
BioSpace
Tue, 01/10/23 - 06:48 pm
Tags:
Merck, JPMHC 2023, Keytruda, vaccines, M&A
JPM23, Day 2: Takeda readies for dengue vaccine launch; Merck touts recent deals
Fierce Pharma
Tue, 01/10/23 - 10:50 am
Tags:
JPMHC 2023, Takeda, vaccines, Roche, GSK, Bayer, Merck
Novo Nordisk, AstraZeneca and Lilly will top pharma's revenue growth in 2023: report
Fierce Pharma
Sun, 01/8/23 - 09:57 pm
Tags:
Pfizer, Merck, JNJ, Novo Nordisk, AstraZeneca
The biggest-selling pharma companies of 2023
EP Vantage
Wed, 01/4/23 - 05:20 pm
Tags:
Pfizer, Merck, JNJ, Novartis, AbbVie, Roche
Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts
Fierce Pharma
Tue, 01/3/23 - 10:10 am
Tags:
Eli Lilly, Merck, PeptiDreams, peptides, drug delivery
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
Biopharma Reporter
Mon, 01/2/23 - 06:41 pm
Tags:
antibody-drug conjugate, Merck, LegoChem Biosciences, Mersana, Amgen, GSK, Janssen
OncoC4 doses first participant in ovarian cancer therapy trial
Clinical Trials Arena
Mon, 01/2/23 - 06:33 pm
Tags:
OncoC4, clinical trials, ONC-392, Merck, Keytruda, ovarian cancer, platinum-resistant ovarian cancer
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
BioSpace
Thu, 12/22/22 - 10:44 am
Tags:
Merck, China, Kelun-Biotech, antibody-drug conjugate, oncology
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay
Fierce Pharma
Wed, 12/21/22 - 12:40 pm
Tags:
AstraZeneca, Merck, Lynparza, Europe, prostate cancer, advanced prostate cancer
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Fierce Biotech
Wed, 12/21/22 - 11:29 am
Tags:
Merck, NGM Biopharmaceuticals, clinical trials, eye disease, NGM621, geographic atrophy
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
Fierce Pharma
Thu, 12/15/22 - 11:01 am
Tags:
AstraZeneca, Merck, Lynparza, FDA, metastatic castration-resistant prostate cancer
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
Fierce Biotech
Tue, 12/13/22 - 10:35 am
Tags:
Merck, Moderna Therapeutics, MRNA, cancer immunotherapy, Keytruda, melanoma
Merck initiates cash tender offer to buy Imago BioSciences
Pharmaceutical Business Review
Tue, 12/13/22 - 10:26 am
Tags:
Merck, M&A, Imago BioSciences

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.